Compare Abbott Laboratories (ABT) vs Marriott International Inc (MAR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Marriott International Inc — how do they compare? Abbott Laboratories trades at $95.46 (market cap $166.94B), while Marriott International Inc trades at $371.35 (market cap $100.40B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | MAR | |
|---|---|---|
Market Cap | $166.94B | $100.40B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $402.54 |
52-Week Low | $82.57 | $255.35 |
Enterprise Value | $193.69B | $117.35B |
Dividend Yield | 2.63% | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Marriott International (MAR) trades at $380.75, up 2.09% today, near its consensus price target of $386.42. The stock shows a bullish technical trend with strong moving averages, while fundamentals reveal robust revenue growth to $26.19B in 2025 and a net income margin of 9.72%. Recent developments include a strategic beverage agreement with Coca-Cola and the launch of an AI-powered travel search tool, Ask Bonvoy, enhancing its digital offerings.
The outlook for MAR is positive with analyst consensus leaning bullish (44% Buy ratings), though high debt levels and owner disputes over the Bonvoy loyalty program pose risks. Earnings beats in recent quarters support growth, but valuation metrics like a P/E of 39.76 suggest premium pricing. Investors should weigh solid operational cash flow against escalating liabilities for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
